Evaluation of Preprocedural Laboratory Parameters as Predictors of Drug-Eluting Stent Restenosis in Coronary Chronic Total Occlusion Lesions

Angiology. 2019 Mar;70(3):272-278. doi: 10.1177/0003319717752245. Epub 2018 Jan 16.

Abstract

This retrospective, single-center study assessed the prognostic value of several emerging inflammatory markers as predictors of in-stent restenosis (ISR) after drug-eluting stent implantation for coronary chronic total occlusion (CTO) lesions. Consecutive patients (n = 416) who underwent successful percutaneous coronary intervention (PCI) for documented CTO lesions and with follow-up angiography were enrolled. Preprocedural high-sensitivity C-reactive protein (hsCRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and red cell distribution width (RDW) were analyzed. At mean follow-up of 14.4 ± 3.3 months, ISR occurred in 72 patients. Compared with the non-ISR group, preprocedural hsCRP level, PLR, NLR, and RDW were significantly higher in the ISR group. The ISR group also had significantly greater proportions of patients with diabetes and smoking history, lower estimated glomerular filtration rate, higher low-density lipoprotein cholesterol (LDL-C) level and neutrophil count, longer stent length, and higher rate of severe dissection. In multivariate analysis, NLR (odds ratio [OR]: 3.110; 95% confidence interval [CI], 2.102-4.063; P < .001) and PLR (OR: 1.029; 95% CI, 1.016-1.143; P < .001) were independent predictors of ISR, along with LDL-C level and stent length. In conclusion, higher preprocedural NLR and PLR levels were independent risk factors for the development of ISR in patients who underwent PCI for CTO lesions.

Keywords: coronary chronic total occlusion (CTO); in-stent restenosis (ISR); neutrophil-to-lymphocyte ratio (NLR); platelet-to-lymphocyte ratio (PLR).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Coronary Angiography / adverse effects
  • Coronary Restenosis / diagnosis
  • Coronary Restenosis / etiology
  • Coronary Restenosis / pathology*
  • Drug-Eluting Stents* / adverse effects
  • Female
  • Humans
  • Lymphocytes / pathology*
  • Male
  • Neutrophils / pathology
  • Percutaneous Coronary Intervention / methods
  • Risk Factors